Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Saved in:

Bibliographic Details
Main Authors:	Jesse Haramati, Fabiola Solorzano-Ibarra, Dallas B. Flies
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	ICI Immunotherapy cancer tumor personalized & precision medicine checkpoint blockade (ICB) therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma
by: Yiming Liu, et al.
Published: (2025-02-01)

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
by: Zongfu Pan, et al.
Published: (2025-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer
by: Lulu Zhang, et al.
Published: (2025-02-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis
by: Zhenli Li, et al.
Published: (2024-05-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy
by: Weijian Zhu, et al.
Published: (2025-02-01)

Vaccine adjuvants for immunotherapy: type, mechanisms and clinical applications
by: Nimeet Desai, et al.
Published: (2025-02-01)

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01)

MECHANISMS AND CLINICAL PERSPECTIVES OF ALLERGEN-SPECIFIC IMMUNOTHERAPY
by: Leila Akhvlediani, et al.
Published: (2024-12-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
by: Yo-Ting Tsai, et al.
Published: (2024-03-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
by: Linghua Wang, et al.
Published: (2023-08-01)

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
by: Xiaolin Liu, et al.
Published: (2025-02-01)

Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy
by: Yonghua Cai, et al.
Published: (2025-02-01)

Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy
by: Minfeng Yang, et al.
Published: (2025-02-01)

Differentially expressed microRNAs in pre-transplant lung biopsies target immune checkpoint proteins and can predict primary graft dysfunction in lung transplantation
by: Vitale Miceli, et al.
Published: (2025-02-01)

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
by: Hidekazu Hirano, et al.
Published: (2025-02-01)

Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study
by: Biling Gan, et al.
Published: (2025-02-01)

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era
by: Amy Alabaster, et al.
Published: (2024-01-01)

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
by: Preston Ngo, et al.
Published: (2025-02-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01)

Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of the Meet-Uro 15 study
by: Martina Catalano, et al.
Published: (2025-02-01)

Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
by: Pengliang Xu, et al.
Published: (2025-02-01)

Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity
by: Yujia Zhao, et al.
Published: (2025-02-01)

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01)

Echinococcal Cyst Blockade — the Rare Cause of Acute Pancreatitis and Obstructive Jaundice
by: S. A. Budzinskiy, et al.
Published: (2023-11-01)